1999
DOI: 10.1038/sj.leu.2401452
|View full text |Cite
|
Sign up to set email alerts
|

Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies

Abstract: Both clinical and experimental evidence indicate that T lymphocytes can mediate antileukemic effects in acute myelogenous leukemia (AML). These antileukemic effects can be either nonspecific cytotoxicity (killer cell activity) or reactivity against leukemia-specific antigenic peptides presented by self-HLA molecules. The antigen-specific T cell activation requires recognition of specific peptides together with costimulatory signalling. For most patients the AML blasts express both HLA class I and class II mole… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
23
0

Year Published

2000
2000
2014
2014

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(23 citation statements)
references
References 86 publications
0
23
0
Order By: Relevance
“…Although native AML blasts with a phenotype consistent with progenitors of dendritic Langerhans' cells have been described [78], this phenotype seems to be very rare. Native AML blasts usually express only some of the membrane molecules needed for initiation of T cell activation, including the peptide-presenting HLA class I and class II molecules and the T cell binding CD58 molecule, but in most cases the AML blasts do not express the costimulatory B7 (CD80 and CD86) and CD45 molecules [72,79]. One possible approach for enhancement of AML-specific T cell reactivity would therefore be to induce a dendritic cell phenotype in AML blasts, and thereafter to use these modulated cells for presentation of leukemia-specific antigens to T cells (Table 2).…”
Section: Differentiation Induction and Immunotherapy In Amlmentioning
confidence: 99%
“…Although native AML blasts with a phenotype consistent with progenitors of dendritic Langerhans' cells have been described [78], this phenotype seems to be very rare. Native AML blasts usually express only some of the membrane molecules needed for initiation of T cell activation, including the peptide-presenting HLA class I and class II molecules and the T cell binding CD58 molecule, but in most cases the AML blasts do not express the costimulatory B7 (CD80 and CD86) and CD45 molecules [72,79]. One possible approach for enhancement of AML-specific T cell reactivity would therefore be to induce a dendritic cell phenotype in AML blasts, and thereafter to use these modulated cells for presentation of leukemia-specific antigens to T cells (Table 2).…”
Section: Differentiation Induction and Immunotherapy In Amlmentioning
confidence: 99%
“…Studies of in vitro cultured acute myelogenous leukemia (AML) cell lines and native blasts have been important for the characterization of proliferation, differentiation, and apoptosis in leukemic hematopoiesis, and for our understanding of chemotherapy effects in AML [1][2][3][4][5][6]. One would also expect experimental studies to become important in the future characterization of genetic abnormalities as pathogenetic factors in AML [3,4], and based on the in vitro results several new therapeutic strategies have already been suggested [1,5,6].…”
Section: Introductionmentioning
confidence: 99%
“…One would also expect experimental studies to become important in the future characterization of genetic abnormalities as pathogenetic factors in AML [3,4], and based on the in vitro results several new therapeutic strategies have already been suggested [1,5,6]. Furthermore, in vitro growth characteristics of native AML blasts may be useful as a prognostic parameter in AML…”
Section: Introductionmentioning
confidence: 99%
“…For most patients, AML cells express both MHC class I and class II molecules required for antigen presentation. 8,9 However, they lack the expression of co-stimulatory ligands or inflammatory cytokines to promote strong immune responses. In fact, expression of the co-stimulatory ligand CD80 has been reported to occur in less than 10% of analyzed AML samples.…”
Section: Introductionmentioning
confidence: 99%